Advance Online
Advance Online

New Treatment Option for Adolescents

LEXETTE® foam is now available for use in adolescents.

On September 21, 2021 Mayne Pharma announced that the U.S. Food and Drug Administration (FDA) approved LEXETTE® (halobetasol propionate) foam, 0.05% for the treatment of plaque psoriasis in patients aged 12 years and older.

Topical steroids are classified by potency. LEXETTE is classified as a super potent topical corticosteroid, making it one of the topical steroid treatments with the highest potency available. It was originally approved by the FDA in 2018, based on evidence from multicenter, randomized, double-blind, vehicle-controlled studies. A follow-on open label study in adolescent patients (12-17 years) with plaque psoriasis provided additional data [1], resulting in approval and thus providing another option for this population.

Learn More About Treatments

Treatments for children, adolescents, and adults vary. Learn more about psoriasis treatment options.

Psoriasis treatments

Reference

1.      https://www.maynepharma.com/media/2648/fda-approves-lexette-for-adolescent-plaque-psoriasis.pdf

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.